BUZZ-Mylan NV: Pricing actions could bring regulatory scrutiny - Wells Fargo
** Generic drugmaker's shares down 5 pct at $43.43
** Mylan could become target of regulators, the media and patient advocacy groups for aggressive pricing actions, Wells Fargo analysts say
** The company has raised prices on seven products by more that 100 pct and on 24 products by more than 20 pct in the last six months, analysts write, citing pricing data from Medi-Span Price Rx
** Valeant Pharmaceuticals International Inc and Turing Pharma have already taken a lot of heat for steeply raising drug prices and are under intense regulatory scrutiny
** Analysts ask if aggressive price increases are being used to meet EPS targets or to offset disappointing sales in other areas
** Up to Thursday's close, stock had fallen 38 pct this year
© Thomson Reuters 2017 All rights reserved.